Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 2/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27945207 | 0.79 | TSHR (0.55) | TSHRPOLBALDH1A1MPOL3MBTL1 | |
| SCHEMBL8682782 | 0.78 | TSHR (0.46) | TSHRPOLBALDH1A1MPOTLR7 | |
| SCHEMBL3023761 | 0.78 | TLR7 (0.50) | TSHRMPOTLR7NCF1NUDT1 | |
| Hydrochloric Acid SCHEMBL3231113 | 0.77 | TLR7 (0.49) | TSHRMPOTLR7NCF1NUDT1 | |
| SCHEMBL28872949 | 0.77 | SCN9A (0.52) | TSHRALDH1A1MPOLMNANUDT1 | |
| SCHEMBL28414968 | 0.73 | LDHA (0.62) | TSHRALDH1A1LMNATDP1NCF1 | |
| SCHEMBL28407655 | 0.73 | NPY5R (0.51) | POLBALDH1A1TDP1L3MBTL1LDHA | |
| SCHEMBL6380647 | 0.73 | TLR7 (0.45) | TSHRMPOTLR7NCF1NUDT1 | |
| SCHEMBL5664802 | 0.73 | TLR7 (0.40) | TSHRPOLBALDH1A1MPOTLR7 | |
| SCHEMBL27929761 | 0.71 | TLR8 (0.47) | TSHRALDH1A1KDM1AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493443-B | Application of erlotinib derivative in preparation of medicines for treating esophageal cancer | 侯延生 | 2023-06-27 | — | — | CN | claimed |
| CN-113912554-A | Erlotinib hydrochloride synthesis and refining process | 湖北一半天制药有限公司 | 2022-01-11 | — | — | CN | claimed |
| CN-113493443-A | Erlotinib derivative with killing performance on wild lung cancer tumor cells and preparation method thereof | 侯延生 | 2021-10-12 | — | — | CN | claimed |
| CN-111875588-A | Erlotinib derivative with killing performance on wild lung cancer tumor cells and preparation method thereof | 侯延生 | 2020-11-03 | — | — | CN | claimed |
| CN-111333630-A | Erlotinib derivative with killing performance on wild lung cancer tumor cells and preparation method thereof | 侯延生 | 2020-06-26 | — | — | CN | claimed |
| CN-113493443-B | Application of erlotinib derivative in preparation of medicines for treating esophageal cancer | 侯延生 | 2023-06-27 | — | — | CN | disclosed |
| CN-113149965-B | Erlotinib derivative and application thereof in preparation of IDO1 activity inhibition drugs and antitumor drugs | 南方医科大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-113912554-A | Erlotinib hydrochloride synthesis and refining process | 湖北一半天制药有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-113912554-A | Erlotinib hydrochloride synthesis and refining process | 湖北一半天制药有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-113493443-A | Erlotinib derivative with killing performance on wild lung cancer tumor cells and preparation method thereof | 侯延生 | 2021-10-12 | — | — | CN | disclosed |
| CN-113149965-A | Erlotinib derivative and application thereof in preparation of IDO1 activity inhibition drugs and antitumor drugs | 南方医科大学 | 2021-07-23 | — | — | CN | disclosed |
| CN-111875588-A | Erlotinib derivative with killing performance on wild lung cancer tumor cells and preparation method thereof | 侯延生 | 2020-11-03 | — | — | CN | disclosed |
| CN-111333630-A | Erlotinib derivative with killing performance on wild lung cancer tumor cells and preparation method thereof | 侯延生 | 2020-06-26 | — | — | CN | disclosed |